We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesPuma Biotechnology Inc

Puma Biotechnology Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.19 USD 0.11 ( 1.36%)
Last update at 2026-11-12T15:45:00Z
VOLUME
54297
Market Cap
193.92M
P/E
12.56

Momentum Score

…

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.08
Low
8.25
High
52 Week Price Range
2.13
Low
7.73
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Puma Biotechnology develops and commercializes targeted oncology therapies, principally the oral HER2-directed tyrosine kinase inhibitor neratinib, and focuses on regulatory approvals, label expansions and partnering to grow sales. Long-term growth may be supported by new indications, international commercialization and business development, so investors may find exposure to a commercial-stage oncology asset with upside from trial and regulatory outcomes.

Key risks include clinical and regulatory setbacks, intense competition in HER2-targeted oncology, revenue concentration on a single approved product, potential patent and exclusivity challenges, and the company's need for ongoing financing if sales do not scale.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.08
Dividend Yield
-
Revenue TTM
226.63M
Revenue Per Share
4.77
Gross Profit TTM
172.94M
Debt / Equity
2.09
ROE
40.02%
Net Debt
26.91M
ROCE
18.07%
Diluted EPS TTM
0.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 0.50M -28.80M -59.80M -75.60M -113.60M
Net income 0.91M -29.10M -60.00M -82.72M -113.60M
Selling general administrative 89.98M 116.29M 118.49M 140.51M 146.19M
Selling and marketing expenses 0.02M 0.01M 0.09M 1.19M 0.01M
Gross profit 172.90M 189.50M 185.70M 235.50M 216.40M
Reconciled depreciation 8.92M 10.60M 10.03M 8.08M 7.38M
Ebit 23.70M -8.90M -30.40M -39.10M -109.98M
Ebitda 31.50M 1.70M -29.50M -36.10M -102.60M
Depreciation and amortization 7.80M 10.60M 0.90M 3.00M 7.38M
Non operating income net other -11.67M -17.29M -15.34M -21.48M -7.92M
Operating income 23.70M -8.90M -30.40M -39.10M -94.70M
Other operating expenses 197.30M 251.90M 255.50M 311.40M 345.70M
Interest expense 11.50M 12.80M 14.10M 15.00M 11.00M
Tax provision 0.46M 0.32M 0.20M - -
Interest income 0.81M 0.16M 0.50M 2.85M 1.80M
Net interest income -10.78M -12.65M -13.60M -12.17M -9.19M
Non recurring 7.00M - - - -
Income tax expense 0.50M 0.30M 0.20M 7.12M -7.92M
Total revenue 228.00M 253.20M 225.10M 272.30M 251.00M
Total operating expenses 142.20M 188.20M 216.10M 274.60M 311.10M
Cost of revenue 55.10M 63.70M 39.40M 36.80M 34.60M
Total other income expense net -23.20M -19.90M -29.40M -36.50M -9.70M
Net income from continuing ops 0.00M -29.13M -59.99M -75.59M -113.58M
Net income applicable to common shares 0.00M -29.13M -59.99M -75.59M -113.58M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 230.53M 222.06M 226.59M 244.22M 234.91M
Intangible assets 60.87M 70.61M 66.12M 74.14M 40.46M
Other current assets 4.68M 1.95M 2.58M 2.70M 2.73M
Total liab 177.09M 200.45M 229.03M 250.17M 217.44M
Total stockholder equity 53.44M 21.60M -2.40M -6.00M 17.50M
Deferred long term liab - - 0.74M 0.95M 0.87M
Other current liab 53.70M 66.90M 2.26M 2.48M 69.03M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -1345.16M -1366.76M -1366.76M -1337.63M -1277.64M
Other liab - 12.83M 6.38M 32.34M 9.00M
Other assets 0.00M 4.66M 4.67M 5.06M 6.32M
Cash 84.58M 76.20M 63.10M 85.30M 60.00M
Total current liabilities 99.38M 77.48M 109.59M 114.25M 90.84M
Current deferred revenue - 5.90M 92.58M 82.32M -
Net debt 26.91M 38.08M 53.54M 35.65M 60.23M
Short term debt 38.80M 4.14M 3.57M 17.38M 2.62M
Short long term debt 34.00M - - 14.29M -
Short long term debt total 111.49M 114.28M 116.64M 120.95M 120.23M
Other stockholder equity 1398.61M 1388.35M 1364.36M 1331.63M 1295.07M
Property plant equipment - 1.15M 15.77M 2.48M 3.30M
Total current assets 156.19M 134.28M 140.02M 146.14M 166.30M
Net tangible assets - 21.61M -68.57M -80.09M -23.00M
Short term investments 11.35M 4.87M 18.98M 8.10M 51.60M
Net receivables 48.49M 42.27M 32.53M 25.54M 28.90M
Long term debt 65.66M 98.31M 97.09M 84.03M 94.96M
Inventory 7.08M 4.53M 7.11M 3.45M 3.17M
Accounts payable 6.89M 6.44M 11.17M 12.08M 19.18M
Accumulated other comprehensive income -0.00M - -0.00M - 0.06M
Common stock total equity - 0.01M 0.00M 0.00M 0.00M
Retained earnings total equity - -1366.76M -1366.76M -1337.63M -1277.64M
Non currrent assets other 2.73M 4.66M 4.67M 5.06M 6.32M
Non current assets total 74.34M 87.78M 86.56M 98.08M 68.61M
Capital lease obligations 11.83M 15.97M 19.55M 22.64M 25.27M
Long term debt total - - 97.09M 84.03M 94.96M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 14.10M -10.88M 43.45M 5.47M -57.01M
Change to liabilities -37.80M -0.90M 12.14M 21.07M 8.78M
Total cashflows from investing activities 7.10M -10.88M 23.40M 5.16M -57.62M
Net borrowings - -1.50M -1.50M -68.42M 100.80M
Total cash from financing activities 12.20M -31.90M 0.10M -67.10M 108.40M
Change to operating activities -33.60M 9.94M 18.20M 33.48M 13.56M
Net income 0.00M -29.13M -59.99M -75.59M -113.58M
Change in cash 3.50M -22.16M 24.24M -39.53M 26.72M
Begin period cash flow 75.29M 97.45M 73.21M 112.74M 86.02M
End period cash flow 78.79M 75.29M 97.45M 73.21M 112.74M
Total cash from operating activities -15.80M 20.70M 0.80M 22.40M -24.10M
Issuance of capital stock 12.50M - - - 0.00M
Depreciation 8.92M 10.60M 10.03M 8.08M 7.38M
Other cashflows from investing activities -7.00M - -20.05M -0.31M 5.20M
Change to inventory 2.58M -3.65M -0.28M -0.55M -0.60M
Change to account receivables -7.82M -5.98M 2.35M -8.12M -11.10M
Sale purchase of stock 12.22M - 0.07M 1.35M 7.65M
Other cashflows from financing activities -0.30M 68.10M 8.54M 12.90M 108.40M
Change to netincome 18.83M 39.78M 37.58M 66.61M 87.23M
Capital expenditures 7.00M 0.00M 20.05M 0.31M 0.61M
Change receivables -7.82M -5.98M 2.35M -8.12M -11.10M
Cash flows other operating -0.54M 4.73M -1.05M 10.88M -2.22M
Cash and cash equivalents changes 3.50M -22.16M 24.24M -39.53M 26.72M
Change in working capital -43.58M -0.60M 13.16M 23.28M -5.14M
Stock based compensation 11.83M 32.63M 36.58M 57.33M 86.94M
Other non cash items 7.03M 7.20M 1.03M 9.31M 0.29M
Free cash flow -22.80M 20.70M -19.25M 22.09M -24.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PBYI
Puma Biotechnology Inc		 0.11
1.36%		 8.19 12.56 10.13 1.08 4.75 1.14 5.67
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024

424-248-6500

https://www.pumabiotechnology.com

185

Name Title Year Born
Mr. Alan H. Auerbach Founder, Chairman, Pres, CEO & Sec. 1970
Mr. Maximo F. Nougues CFO & Principal Accounting Officer 1969
Dr. Alvin F. Wong Pharm.d. Chief Scientific Officer NA
Mr. Douglas Hunt B.Sc., FRAPS Sr. VP of Regulatory Affairs, Medical Writing & Project Management 1965
Mr. Jeffrey Jerome Ludwig Chief Commercial Officer 1966
Mr. Mariann Ohanesian Sr. Director of Investor Relations NA
Mr. Alan H. Auerbach Founder, Chairman, President, CEO & Secretary 1970
Dr. Alvin F. Wong Pharm.d. Chief Scientific Officer 1953
Mr. Douglas Hunt B.Sc., FRAPS Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law 1965
Mr. Mariann Ohanesian Senior Director of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…